Medipal stock gets a new CEO as October 1 reshuffle takes effect

Medipal Holdings stock (ISIN JP3268950007) was trading at JPY 2,916.50 on the Tokyo Stock Exchange on October 8, 2026 at 10:55 a.m. JST, down JPY 25 from the prior close. The company entered a new leadership phase on October 1, 2026, when a management reshuffle took effect, according to The Globe and Mail.

Leadership changes from October 1

Imagawa became representative director and president, while Shuichi Watanabe moved from president and CEO to representative director and chairman. The transition also changes responsibilities across the pharmaceutical business and financial strategy functions, making governance the immediate company-specific issue for shareholders.

Japan IR states that the president-duty delegation ended on September 30, 2026, with the new representative-director structure taking effect one day later.

Q1 revenue reached JPY 989.5 billion

Medipal's Q1 FY27 revenue was JPY 989.5 billion and earnings were JPY 13.65 billion, according to Yahoo Finance. Investing.com reports quarterly revenue of JPY 989.503 billion versus JPY 905.687 billion in the previous quarter, a 9.25 percent increase.

The same financial summary lists net income of JPY 13.646 billion and earnings per share of JPY 66.7 for the latest quarter. That combination gives the leadership change a measurable operating backdrop, although the net margin remains 1.38 percent in the Q1 FY27 figures shown by Yahoo Finance.

Analysts see JPY 3,145

The consensus on Investing.com comprises one Buy, three Hold ratings and four analysts, with an average 12-month target of JPY 3,145. The target lies 7.84 percent above the October 8 price, giving investors a numerical measure of the gap between the quote and published consensus.

Stock stays below the yearly high

Medipal was trading at JPY 2,916.50 on the Tokyo Stock Exchange on October 8, 2026 at 10:55 a.m. JST, with a 52-week range of JPY 2,456.50 to JPY 3,182. The JPY 597.0 billion market capitalization and 75,800-share volume give the leadership transition a market context without turning it into an investment recommendation.

More news and analysis on Medipal stock